# Compare Retatrutide and Tirzepatide — Assent Peptides

> A side-by-side comparison of two Metabolic & Weight Research peptides — retatrutide and tirzepatide — across peptide class, evidence base, regulatory status, and key cautions.

Where retatrutide and tirzepatide share pharmacology, where they differ, and what the current evidence actually shows for each.

## The short version

This page lines up [retatrutide](/retatrutide) and [tirzepatide](/tirzepatide) on the dimensions that matter when reading the research: receptor targets, evidence depth, regulatory standing, and the single most important caution for each. The headline: both are synthetic incretin-class peptides acylated for once-weekly subcutaneous dosing; tirzepatide is FDA-approved across three indications with multiple completed Phase 3 programs; retatrutide adds a glucagon receptor to the dual-receptor scaffold of tirzepatide and is still in Phase 3, with no regulatory approval as of mid-2026 [1][4][9][11]. Neither is presented here with a human dose.

## The comparison matrix

| Dimension | Retatrutide | Tirzepatide |
| --- | --- | --- |
| Peptide class | Triple GIP/GLP-1/glucagon receptor agonist (investigational, 39 aa) | Dual GIP/GLP-1 receptor agonist (FDA-approved, 39 aa) |
| Most-studied in | Obesity, type 2 diabetes, MASLD (Phase 1/2 trials) | Type 2 diabetes, obesity, obstructive sleep apnea (Phase 3 + approved) |
| Evidence base (model) | Phase 2 RCTs; Phase 3 (TRIUMPH) ongoing [1][4][5] | Multiple Phase 3 RCTs completed; head-to-head evidence available [8][11][12] |
| Administration studied | Subcutaneous once weekly (trials: 1, 4, 8, 12 mg doses) [4][6] | Subcutaneous once weekly (approved: 2.5–15 mg escalation schedule) [9] |
| Regulatory status | Investigational. Not approved by FDA or any regulator as of mid-2026 [1] | FDA-approved: T2D (2022), obesity/overweight (2023), obstructive sleep apnea (subsequent) [9] |
| Key caution | No approved indication; unregulated gray-market supply; cardiovascular outcomes data pending [1][4] | Gallbladder/biliary disease signal (RR 1.97 in meta-analysis); lean-mass loss; weight regain on discontinuation [10] |

## Peptide class

Both compounds are 39-amino-acid synthetic peptides acylated with a fatty-diacid moiety for albumin binding and extended half-life, enabling once-weekly dosing. The structural difference is one receptor: tirzepatide agonizes GIP and GLP-1; retatrutide adds glucagon receptor agonism to those two. The glucagon arm adds thermogenic energy expenditure and lipid mobilization — the component that is absent from tirzepatide's pharmacology [1][2][9]. Relative to their native hormones, retatrutide is approximately 8.9× more potent at GIPR, 0.3× at GCGR, and 0.4× at GLP-1R; tirzepatide's GIPR activity is also higher than native GIP, a pharmacological advance over selective GLP-1 agents [2][9].

## Most-studied in

Both are studied in metabolic disease, but trial breadth differs substantially. Tirzepatide has completed Phase 3 programs in type 2 diabetes (SURPASS series), obesity without diabetes (SURMOUNT series), and obstructive sleep apnea, with a head-to-head obesity trial against a higher dose of another approved incretin [8][11][12]. Retatrutide's evidence comes from Phase 2 obesity and type 2 diabetes RCTs and a Phase 2 MASLD substudy [3][4][5], with all pivotal Phase 3 data still pending [1]. Liver-fat reduction (−82.4% at 24 weeks in the MASLD substudy) is a signal that retatrutide has developed further than tirzepatide has in that particular indication [3].

## Evidence base (model)

Tirzepatide has the deeper controlled human evidence. The SURMOUNT-1 trial alone enrolled 2,539 participants and ran 72 weeks; SURPASS-2 included 1,879 adults with T2D; and SURMOUNT-5 directly compared tirzepatide and semaglutide in 751 people with obesity [8][11][12]. Retatrutide's Phase 2 obesity trial enrolled 338 participants over 48 weeks, and its T2D trial 281 over 36 weeks [4][5]. Phase 2 data are informative but not sufficient to characterize the full safety and durability profile that Phase 3 programs provide — a gap that will close only when TRIUMPH reports [1].

## Administration studied

Both compounds are administered subcutaneously, once weekly. Trial doses for retatrutide spanned 1, 4, 8 and 12 mg; the first-in-human study characterized a half-life of approximately 6 days supporting that schedule [4][6]. Tirzepatide's approved titration runs from 2.5 mg at initiation up to 15 mg maintenance; the approximately 5-day half-life is the pharmacokinetic basis for the weekly schedule [9].

## Regulatory status

The regulatory gap between the two is the sharpest distinction on this desk. Tirzepatide is FDA-approved for three indications — type 2 diabetes, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea — and is available as a prescription medicine in the United States and other jurisdictions [9]. Retatrutide is investigational. It has no approved indication, no prescription pathway, and Phase 3 outcome trials are ongoing with no reported results as of mid-2026 [1]. Material labeled as retatrutide in the gray market is unregulated and of unverified identity and purity.

## Key caution

For retatrutide the defining caution is regulatory: it is not approved, Phase 3 is incomplete, long-term cardiovascular and renal outcomes are unknown, and any material outside a clinical trial is unverified [1][4]. For tirzepatide the most clinically salient signal is gallbladder and biliary disease — a statistically significant increase (RR 1.97) across meta-analyzed RCTs — alongside a well-documented lean-mass reduction and substantial weight regain upon discontinuation [10]. Both share GI intolerance as the principal tolerability challenge, and both carry heart-rate and drug-interaction considerations [4][9][10]. Reading them together, the distinction is between an approved agent with a well-characterized benefit-risk profile and an investigational agent whose Phase 3 program will determine whether its larger weight-reduction signal comes at acceptable cost.

---

Literature summaries from peer-reviewed trials. No products. No doses. No medical guidance.